50 related articles for article (PubMed ID: 15328175)
1. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
Sabnis GJ; Goloubeva OG; Kazi AA; Shah P; Brodie AH
Mol Cancer Ther; 2013 Dec; 12(12):2804-16. PubMed ID: 24092810
[TBL] [Abstract][Full Text] [Related]
2. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
[TBL] [Abstract][Full Text] [Related]
3. Invasive Ductal Carcinoma of the Breast in a Transgender Man: A Case Report.
Heng YJ; Zhang KJ; Valero MG; Baker GM; Fein-Zachary VJ; Irwig MS; Wulf GM
Case Rep Oncol; 2023; 16(1):811-817. PubMed ID: 37900827
[TBL] [Abstract][Full Text] [Related]
4. The Tumor Macroenvironment: Cancer-Promoting Networks Beyond Tumor Beds.
Rutkowski MR; Svoronos N; Perales-Puchalt A; Conejo-Garcia JR
Adv Cancer Res; 2015; 128():235-62. PubMed ID: 26216635
[TBL] [Abstract][Full Text] [Related]
5. Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence.
Archer DF; Carr BR; Pinkerton JV; Taylor HS; Constantine GD
Menopause; 2015 Jul; 22(7):786-96. PubMed ID: 25423325
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer and obesity: in vitro interferences between adipokines and proangiogenic features and/or antitumor therapies?
Dubois V; Delort L; Billard H; Vasson MP; Caldefie-Chezet F
PLoS One; 2013; 8(3):e58541. PubMed ID: 23554900
[TBL] [Abstract][Full Text] [Related]
7. Leptin and breast cancer: an overview.
Artac M; Altundag K
Med Oncol; 2012 Sep; 29(3):1510-4. PubMed ID: 21877194
[TBL] [Abstract][Full Text] [Related]
8. Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.
Sabnis GJ; Goloubeva O; Chumsri S; Nguyen N; Sukumar S; Brodie AM
Cancer Res; 2011 Mar; 71(5):1893-903. PubMed ID: 21245100
[TBL] [Abstract][Full Text] [Related]
9. Leptin--from regulation of fat metabolism to stimulation of breast cancer growth.
Sulkowska M; Golaszewska J; Wincewicz A; Koda M; Baltaziak M; Sulkowski S
Pathol Oncol Res; 2006; 12(2):69-72. PubMed ID: 16799705
[TBL] [Abstract][Full Text] [Related]
10. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Kaufmann M; Rody A
Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
[TBL] [Abstract][Full Text] [Related]
11. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
12. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
Núñez NP; Jelovac D; Macedo L; Berrigan D; Perkins SN; Hursting SD; Barrett JC; Brodie A
Clin Cancer Res; 2004 Aug; 10(16):5375-80. PubMed ID: 15328175
[TBL] [Abstract][Full Text] [Related]
13. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
14. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
15. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
